614
Med Chem Res (2011) 20:607–614
Depaulis A, Van Luijtelaar V (2006) Genetic models of absence
epilepsy in the rat. In: Pitkanen A, Schwartzkroin PA, Moshe SL
(eds), Models of seizures and epilepsy, Chap 18. Elsevier, San
Diego, CA, pp 233–248
Dimmock RJ, Vashisththa CS, Stables PJ (2000) Anticonvulsant
properties of various acetylhydrazones, oxamoylhydrazones and
semicarbazones derived from aromatic and unsaturated carbonyl
compounds. Eur J Med Chem 35:241–248
Diouf O, Bourhim M, Lambert DM, Poupaert JH, Stables JP, Vamecq
J (1997) Anticonvulsant and neurotoxicological properties of
4-amino-N-(2-ethylphenyl) benzamide, a potent ameltolide ana-
logue. Biomed Pharmacother 51(3):131–136
Finn DA, Gee KW (1994) The estrous cycle, sensitivity to convul-
sants and the anticonvulsant effect of a neuroactive steroid.
J Pharmacol Exp Ther 271:164–170
Department of Pharmacology and Clinical Pharmacology.
Four to twelve months old GAERS were used in the
experiments. Animals were anesthetized by ketamine
(100 mg/kg i.p.) and chlorpromazine (1.0 mg/kg, i.p.) and
placed on a stereotaxic instrument (Stoelting, Model 51600,
USA). Four stainless steel screws were bilaterally placed on
the frontal and parietal cortex for the EEG recordings.
These screw-electrodes were connected to a microconnec-
tor. Canula, microconnector and screws were fixed to the
cranium by acrylic cement. The animals were allowed to
recover at least 1 week after the operation. On the day of the
experiment, a 30-min basal EEG was recorded from the
animals and then DMSO (control solution) or compound 3
(100 or 150 mg/kg, i.p.) was injected. After those injec-
tions, the EEG was recorded continuously for 2 h. The
cumulative duration of SWDs was calculated before (basal
duration) and after the injection for 20 min time intervals.
˘
˘
Koc¸yigit-Kaymakc¸ıoglu B, Rollas S (2001) Synthesis, characteriza-
tion and evaluation of antituberculosis activity of some hydra-
zones. Farmaco 57:595–599
Kocyigit-Kaymakcioglu B, Toklu HZ, Ikiz S, Bagcigil AF, Rollas S,
Ozgur NY, Ak
S (2008) Synthesis and antinociceptive-
antimicrobial activities of some new amide derivatives of 3,5-
di/-and 1,3,5-trimethylpyrazoles. J Enzym Inhib Med Chem
23(4):454–461
Statistical analysis
˘
˘
˘
˘
¨
Koc¸yigit-Kaymakc¸ıoglu B, Rollas S, Korcegez E, Arıcıoglu F (2005)
Synthesis and biological evaluation of new N-substituted-N0-
(3,5-di/1,3,5-trimethylpyrazole-4-yl)thiourea/urea derivatives.
Eur J Pharm Sci 26(1):97–103
Data are represented as mean SEM and statistically
evaluated by analysis of variance (ANOVA) (GraphPad
Software Prism 4.0, San Diego, USA). In the MES and
PTZ groups, the treatment effect was evaluated by one-way
ANOVA followed by post hoc Bonferroni test.
Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA (1978)
Antiepileptic drug development: 11. Anticonvulsant drug screen-
ing. Epilepsia 19: 409–428
Medina AE, Manhaes AC, Schmidt SL (2001) Sex differences in
sensitivity to seizures elicited by pentylenetetrazol in mice.
Pharmacol Biochem Behav 68:591–596
Cumulative durations of SWDs were evaluated as %
change from the basal duration of SWDs in each group.
The statistical analysis between the groups in GAERS was
performed using two-way ANOVA followed by the post
hoc Bonferroni test. The level of statistical significance was
considered to be P \ 0.05.
Medina MT, Duron RM, Martinez L, Osorio JR, Estrade AL, Zuniga
C, Holden KR (2005) Prevalence, incidence, and etiology of
´
epilepsies in rural Honduras: the Salama Study. Epilepsia
46:124–131
Pandeya SN, Mishra V, Sign PN, Rupainwar DC (1998) Anticonvul-
sant activity of thioureido derivatives of acetophenone semicar-
bazone. Pharmacol Res 37(1):17–22
Acknowledgements The authors thank Marmara University Sci-
entific Research Projects Commission (BAPKO, Project number
SAG-BGS-270605-0132) for the financial support of this study and to
Prof. R.W. Guillery for his valuable comments on the manuscript.
Pandeya SN, Manjula H, Stables JP (2001) Design of semicarbazones
and their bioisosteric analogues as potential anticonvulsants.
Pharmazie 56(2):121–124
Robertson DW, Leander JD, Lawson RR, Beedle EE, Clark CD, Potts
B, Parli CJ (1987) Discovery and anticonvulsant activity of the
potent metabolic inhibitor 4-amino-N-(2,6-dimethylphenyl)-3,5-
dimethylbenzamide. J Med Chem 30:1742–1746
Robertson DW, Beedle EE, Krushinski JH, Lawson RR, Parli CJ,
Potts B, Leander JD (1991) Synthesis and pharmacological
evaluation of a major metabolite of ameltolide, a potent
anticonvulsant. J Med Chem 34(4):1253–1257
Vamecq J, Lambert D, Poupaert JH, Masereel B, Stables JP (1998)
Anticonvulsant activity and interactions with neuronal voltage-
dependent sodium channel of analogues of ameltolide. J Med
Chem 41(18):3307–3313
References
Clark CD, Davenport TW (1987) Synthesis and anticonvulsant
activity of analogues of 4-amino-N-(1-phenylethyl)benzamide.
J Med Chem 30:1214–1218
Clark CD, Lin C, Sansom T (1986) Anticonvulsant activity of 2- and
3-aminobenzanilides. J Med Chem 29:1534–1537
Daidone G, Bajardi ML, Plescia S, Rafa D, Schillaci D, Maggio B,
Benetollo F, Bombieri G (1996) One-step synthesis, crystallo-
graphic studies and antimicrobial activity of new 4-diazopyraz-
ole derivatives. Eur J Med Chem 31:461–468
Danober L, Deransart C, Depaulis A, Vergnes M, Marescaux C
(1998) Pathophysiological mechanisms of genetic absence
epilepsy in the rat. Prog Neurobiol 55(1):27–57
Vamecq J, Bac P, Herrenknecht C, Maurois P, Delcourt P, Stables J
(2000) Synthesis and anticonvulsant and neurotoxic properties of
substituted N-phenyl derivatives of the phthalimide pharmaco-
phore. J Med Chem 43(6):1311–1319
123